Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial
Related Posts
Ronco C, Maduell F, Kalantar-Zadeh K, Madero M, Reis T. The Role of Online Hemodiafiltration in Contemporary Kidney Care. Clin J Am Soc Nephrol. 2025[...]
Everett E, Tiu RA, Zhu B, Feng J, Jackson N, Graham J, Ipp E, Mathioudakis N, Bui AAT, Moin T. Developing and Evaluating a Natural[...]
Wang M, Tang WHW, Li XS, de Oliveira Otto MC, Lemaitre RN, Fretts A, Nemet I, Sotoodehnia N, Sitlani CM, Budoff M, DiDonato JA, Wang[...]